JPRN-UMIN000012752
Completed
Phase 2
A multicenter phase II trial of everolimus for unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-based regimen - NECTOR
ational Cancer Center Hospital East0 sites25 target enrollmentJanuary 6, 2014
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- nresectable pancreatic neuroendocrine carcinoma
- Sponsor
- ational Cancer Center Hospital East
- Enrollment
- 25
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) NET G1 or G2 by WHO 2010 criteria 2\) Interstitial pneumonia or plumonary fibrosis 3\) Metastasis to the central nervous system 4\) Concomitant malignancy within 3 years 5\) Active infection (exept for hepatitis B or C viral infection) 6\) Active gastrointestinal ulcer 7\) Severe or uncontrollable complications, such as cardiovascular impairment, infection, diabetes mellitus, and pulmonary disease 8\) Severe mental disorder 9\) Continuous administration of steroid or immunosuppressant 10\) Prior treatment of mTOR inhibitor 11\) Pregnant or lactating women and women of childbearing age who were not using effective contraception 12\) Patients who was judged to be inappropriate for this study by each investigators
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
evaluation of the activity of Everolimus as maintenance therapy for metastatic neuroendocrine carcinoma with pulmonary or gastroenteropancreatic origin.The aim of this study is to evaluate the activity of a maintenance therapy with everolimus 10 mg daily in patients with stable disease, partial response or complete response after 6 cycles of induction chemotherapy with cisplatin or carboplatin plus etoposide administered according to clinical practice.Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-003951-72-ITGruppo Oncologico Italiano Ricerca Cancro (GOIRC)
Completed
Phase 2
A phase 2 trial of EVERolimus alternating with SUNitinib as first line therapy for advanced renal cell carcinomaACTRN12609000643279The University of Sydney55
Terminated
Phase 2
Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine TumorsGastrointestinal TumorsPancreatic TumorsGastrointestinal Neuroendocrine TumorsPancreatic Neuroendocrine TumorsNCT01648465Hellenic Cooperative Oncology Group25
Completed
Phase 2
Everolimus for Patients With Relapsed/Refractory Germ Cell CancerTesticular CancerGerm Cell CancerNCT01242631Hannover Medical School25
Unknown
Phase 1
Everolimus and Capecitabine in Patients With Advanced MalignancyAdvanced MalignanciesNCT01079702Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)35